Key Drivers
- High profitability
- Near‑net cash
- Elevated multiples
AIAI Summary
TMDX has shifted from a pure clinical‑option story into a scaled commercial, cash‑generative platform where near‑term FCF breakeven (late‑2026/early‑2027) and recurring consumable/logistics economics are now primary valuation drivers; investors should therefore trade the stock on execution of commercial scale and margin expansion rather than solely on trial outcomes. Key actionable watch‑points: verify sustained gross‑margin recovery toward ~60% as consumables and fleet utilization scale, and confirm progression to breakeven without meaningful equity dilution (or major IDE/trial setbacks) over the next 12–18 months.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Near‑net cash
- •Elevated multiples
TMDX delivers exceptionally high margins and strong free‑cash conversion with near‑net cash liquidity, but carries elevated valuation multiples and signs of one‑off quarterly gains that may not be sustainable. #cash-rich
Price Behavior
Key Price Behavior Insights:
- •Below last month
- •Recent strong sell-off
- •Support cluster holds
Price trades well below the last month simple moving average (~$131.40) after a rapid ~23% drop from ~$148.00 to $113.90, leaving downside risk elevated with near-term support at $113.20–$114.00 and resistance at $140.00–$148.00.
Rapid ~23% decline from ~$148.00 (2026-03-03) to $113.90 (2026-03-20) suggesting elevated volatility
Sentiment & News
Key News Insights:
- •Revenue beat
- •FCF breakeven
- •Dilution risk
TransMedics reported 32% revenue growth and an EPS beat, guided 20–25% top‑line growth and nearing FCF breakeven with margin expansion ahead, driving institutional buying and stock momentum despite a weak balance sheet and potential ~15% dilution.
Improving fundamentals and technical interest should support the stock, but balance‑sheet weakness and possible dilution could limit near‑term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings